Phio Pharmaceuticals Corp (NASDAQ:PHIO) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totalling 718,900 shares, a drop of 8.2% from the June 15th total of 783,300 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average trading volume of 221,900 shares, the short-interest ratio is presently 3.2 days.

Separately, ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

Shares of NASDAQ:PHIO traded up $0.01 on Tuesday, hitting $0.40. The company’s stock had a trading volume of 29,800 shares, compared to its average volume of 437,871. The firm’s 50-day moving average price is $0.39. Phio Pharmaceuticals has a 1 year low of $0.27 and a 1 year high of $2.36. The stock has a market cap of $9.44 million, a P/E ratio of -0.38 and a beta of 1.84. The company has a quick ratio of 8.52, a current ratio of 8.52 and a debt-to-equity ratio of 0.04.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $0.02 million during the quarter. Sell-side analysts anticipate that Phio Pharmaceuticals will post -0.36 earnings per share for the current year.

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Phio Pharmaceuticals Corp (NASDAQ:PHIO) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 238,544 shares of the company’s stock, valued at approximately $107,000. Virtu Financial LLC owned approximately 1.07% of Phio Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.51% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Featured Story: The Structure of a Futures Contract

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with's FREE daily email newsletter.